- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Study Endorses HPV Testing for All Women Over 30
New DNA tests looking for the virus responsible for most cases of cervical cancer make sense for all women aged 30 or over, since they can prevent more cases of cancer than smear tests alone, Dutch researchers said on Thursday.
Results of a 5-year study involving 45,000 women provided the strongest evidence yet in favor of using human papillomavirus (HPV) testing, Chris Meijer and colleagues from the VU University Medical Centre in Amsterdam reported in The Lancet Oncology.
Most cases of infection with the sexually transmitted virus are cleared naturally by the immune system, but persistent infection with certain HPV strains can lead to cervical cancer.
The researchers, who looked at women aged 29 to 56, said use of HPV tests led to earlier detection of pre-cancerous lesions, allowing for treatment that improved protection against cancer.
Read more at: http://www.reuters.com/article/2011/12/15/us-hpv-idUSTRE7BE00320111215
Source: Reuters
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Overcoming CAR T Manufacturing Failure in LBCL
March 21st 2025Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Read More
